SavedAdd your journal

Journals / Adnan Menderes Üniversitesi Tıp Fakültesi Dergisi / 2000 / Cilt: 1 - Sayı: 2

Effects of activation of CD30 signaling pathway on CD30+ cutaneous anaplastic large cell lymphoma cell lines

CD30 İletişim yolu aktivasyonunun CD30+ anaplastik büyük hücreli deri lenfoması hücre serilerine etkileri

Edi LEVİ
Marshall E. KADIN
Walther M. PFEIFER
Pages
33–37
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These results suggest that TGF-b may interact with the CD30 signaling pathway in the pathogenesis of cutaneous ALCL.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:CD30 activation has pleiotropic effects on different cell lines representing CD30+ lymphomas.
📊
Key Findings & Data:In nodal T-cell anaplastic large cell lymphomas (ALCL), CD30 activation causes cytolysis and decreased proliferation while in Hodgkinís disease there is either no change or proliferation depending on the cell lines.
💡
Conclusion & Impact:These results suggest that TGF-b may interact with the CD30 signaling pathway in the pathogenesis of cutaneous ALCL.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

CD30 activation has pleiotropic effects on different cell lines representing CD30+ lymphomas. In nodal T-cell anaplastic large cell lymphomas (ALCL), CD30 activation causes cytolysis and decreased proliferation while in Hodgkinís disease there is either no change or proliferation depending on the cell lines. Mac-1 and Mac-2A are two clonally related cutaneous CD30+ anaplastic large cell lymphoma cell lines developed from early(Mac-1) and advanced (Mac-2A) disease from the same patient. Mac-1 is sensitive to transforming growth factor-b (TGF-b) mediated growth inhibition while Mac-2A is resistant. Both cell lines secrete an activated form of TGF-$beta$. Our aim was to investigate the effects of CD30 activation on Mac cell lines. Methods: To understand the effects of CD30 activation, Mac cell lines were incubated with a CD30 agonistic antibody (HeFi-1). 3H-thymidine incorporation, tumor necrosis factor receptor associated factor 1 (TRAF1) expression and nuclear factor-kB activity was determined. Results: Mac-1 and Mac-2A showed increased proliferation with HeFi-1 while the nodal ALCL cell lines were inhibited. When Mac-1 cells were incubated with HeFi-1 and TGF-b neutralizing antibody, the proliferative rate markedly increased compared to HeFi-1 only.TGF $beta$ resistant cell line Mac-2A did not show the same increase Mac-1 and Mac-2A had activation of NF-kB binding activity and increased expression of TRAF1 in response to CD30 activation by HeFi-1. Significance: This is the first demonstration of functionality of the CD30 signaling pathway in cutaneous CD30+ ALCLs. Autocrine TGF-b secreted from Mac-1 cells partially inhibits the proliferative signal from CD30 activation. These results suggest that TGF-b may interact with the CD30 signaling pathway in the pathogenesis of cutaneous ALCL.

Özet

Amaç: CD30 aktivasyonu çeşitli CD30+ lenfoma hücre kültürleri üzerinde farklı etkilere sahiptir; nodal T hücreli CD30+ anaplastik büyük hücreli lenfoma hücrelerinde proliferasyon hızında azalmaya ve sitolize, Hodgkin lenfoması hücre kültürlerinde ise proliferasyona yol açar. Mac-1 ve Mac-2A aynı hastanın erken ve geç evre CD30+ cilt lenfomasından elde edilmiş hücre kültürü serileridir. Bu iki hücre serisi klonal olarak ilişkilidir. Mac-1 hücre serisinin büyümesi transforming growth factor-beta (TGF-b) tarafından inhibe edilebilmektedir. Mac-2A ise TGF-b tarafından inhibe edilememektedir. Bu hücre serilerinin CD30 aktivasyonuna nasıl yanıt verdikleri bilinmemektedir. Yöntem: CD30 aktivasyonunun Mac hücre serilerinin büyüme özelliklerine etkilerini araştırmak amacıyla hücreler CD30 aktive edici antikor HeFi-1 ile inkübe edilmiş, 3H-thymidine inkorporasyonu, Tümör nekrozis faktör reseptör assosiye faktör (TRAF1) ekspresyonu ve nükleer faktör-bB (NF-kB) aktivitesi değerlendirilmiştir. Bulgular: Mac-1 ve Mac-2A HeFi-1 ile inkübasyon sonucu artmış bir proliferatif yanıt göstermişlerdir. Kontrol olarak kullanılan nodal anaplastik büyük hücreli lenfoma hücreleri ise büyüme inhibisyonu göstermişlerdir. Mac-1 hücreleri HeFi- ve TGF-b nötralize edici antikorla inkübe edildiklerinde, proliferatif yanıt tek başına HeFi-1 inkübasyonuna oranla ciddi şekilde artmıştır. TGF-b'ya rezistan hücre kültürü Mac-2A ise aynı yanıtı göstermemiştir. Mac-1 and Mac-2A HeFi-1 aracılığıyla CD30 aktivasyonuna NF-kB nükleer bağlanma aktivitesi artımı ve artmış TRAF1 ekspresyonu ile yanıt vermiştir. Sonuç: Bu çalışma CD30+ anaplastik büyük hücreli deri lenfomalarında CD30 iletişim yolunun işlevselliğinin gösterildiği ilk çalışmadır. Mac-1 hücrelerinden otokrin salınan TGF-b CD30 aktivasyonundan doğan proliferatif yanıtı kısmen inhibe etmektedir. Bu sonuçlar TGF-b nın CD30 iletişim sistemi ile interaksiyonu olduğunu ve bunun CD30+ deri lenfomaları patojenezinde bir rol oynayabileceğini de düşündürmektedir.

🔖

Cite This Article

LEVİ, E., KADIN, M. E., PFEIFER, W. M. (2022). Effects of activation of CD30 signaling pathway on CD30+ cutaneous anaplastic large cell lymphoma cell lines. Adnan Menderes Üniversitesi Tıp Fakültesi Dergisi, Cilt: 1 - Sayı: 2, 33–37. https://ajindex.com/articles/429175

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Willemze R, Kerl H, Sterry W et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the EORTC. Blood 1997
  2. Jaffe ES, Harris NL, Diebold J, Muller-Hermelink HK. WHO classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. Am J Clin Path 1999
  3. 111 (Suppl 1): S8-S12. 3.Paulli M, Berti E, Rosso R et al. CD30/Ki-1 positive lymphoproliferative disorders of the skin-clinicopathologic correlation and statistical analysis of 86 cases: A multicentric study from the European Organization for Research and Treatment of Cancer, Cutaneous Lymphoma Project Group. J Clin Oncol 1995
  4. Willemze R, Beljaards RC. Spectrum of primary cutaneous CD30 (Ki-1) - positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment. J Am Acad Dermatol 1993
  5. Cabanillas F, Armitage J, Pugh WC et al. Lympensity to transform into malignant lymphoma. Ann Intern Med 1995
  6. Falini B, Pileri S, Pizzolo G et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995
  7. Smith CA, Gruss HJ, Davis T, et al. CD30 antigen, a marker for Hodgkin’s lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993
  8. Amakawa R, Hakem A, Kundig TM, et al. Impaired negative selection of T cells in Hodgkin’s disease antigen CD30-deficient mice Cell 1996
  9. Gruss HJ, Boiani N, Williams DE et al. Pleiotropic effects of the CD30 ligand on CD30 expressing cells and lymphoma cell lines. Blood 1994
  10. Lee SY, Park CG, Choi Y. T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors. J Exp Med 1996
  11. Davis TH, Morton CC, Miller-Cassman R et al Hodgkin’s disease, lymphomatoid papulosis and cutaneous T cell lymphoma derived from a common T cell clone. N Eng J Med 1992
  12. Newcom SR, Tagra KK, Kadin ME. Neutralizing antibodies against transforming growth factor beta potentiate the proliferation of Ki-1 positive lymphoma cells. Further evidence for negative autocrine regulation by transforming growth factor beta. Am J Pathol 1992
  13. Knaus PI, Lindemann D, DeCoteau JF et al. A domi